Abstract
The impact on adult disease, of prenatal programming and of the environment during infancy has been widely described. Yet the increased morbidity due to this prenatal and neonatal environment seems to occur ever more early. Indeed, recent studies detected the consequences of prenatal programming in childhood, making it also an immediate concern for paediatricians.
This review, focusing on oligonephropathy, aimed to give an up-dated view on when prenatal-programmed morbidity is first detectable, and on possible preventive strategies and treatments. As renal morbidity related to prenatal programming has been diagnosed in early childhood, at only two years old, it is now urgent to evaluate early strategies such as sports, low-protein or iron diets and antiproteinuric drugs, preventing an accentuation of glomerulosclerosis. A yearly follow-up seems appropriate for patients born small for gestation or preterm, including the measure of blood pressure and of albuminuria. A diet preventing protein and salt excess, and a smoking prohibition could delay the onset of glomerulosclerosis. The yearly follow-up would allow to diagnose it early enough to administer angiotensin converting enzyme inhibitors delaying the progression of renal sclerosis.Keywords: Oligonephropathy, low birth weight, hypertension
Current Pediatric Reviews
Title:Nephron Number Reduction and Low Birth Weight: A Concern for the Paediatrician and Beyond
Volume: 8 Issue: 4
Author(s): Rachel Vieux and Jean-Michel Hascoet
Affiliation:
Keywords: Oligonephropathy, low birth weight, hypertension
Abstract: The impact on adult disease, of prenatal programming and of the environment during infancy has been widely described. Yet the increased morbidity due to this prenatal and neonatal environment seems to occur ever more early. Indeed, recent studies detected the consequences of prenatal programming in childhood, making it also an immediate concern for paediatricians.
This review, focusing on oligonephropathy, aimed to give an up-dated view on when prenatal-programmed morbidity is first detectable, and on possible preventive strategies and treatments. As renal morbidity related to prenatal programming has been diagnosed in early childhood, at only two years old, it is now urgent to evaluate early strategies such as sports, low-protein or iron diets and antiproteinuric drugs, preventing an accentuation of glomerulosclerosis. A yearly follow-up seems appropriate for patients born small for gestation or preterm, including the measure of blood pressure and of albuminuria. A diet preventing protein and salt excess, and a smoking prohibition could delay the onset of glomerulosclerosis. The yearly follow-up would allow to diagnose it early enough to administer angiotensin converting enzyme inhibitors delaying the progression of renal sclerosis.Export Options
About this article
Cite this article as:
Vieux Rachel and Hascoet Jean-Michel, Nephron Number Reduction and Low Birth Weight: A Concern for the Paediatrician and Beyond, Current Pediatric Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/157339612803307714
DOI https://dx.doi.org/10.2174/157339612803307714 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry iMethylK-PseAAC: Improving Accuracy of Lysine Methylation Sites Identification by Incorporating Statistical Moments and Position Relative Features into General PseAAC via Chou’s 5-steps Rule
Current Genomics Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research Lock Stock and Barrel of Wound Healing
Current Pharmaceutical Design Editorial (Thematic Issue: The Life Cycle of the Heart Failure Patient)
Current Cardiology Reviews Vitamin D Deficiency: Universal Risk Factor for Multifactorial Diseases?
Current Drug Targets Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Capacity Building in Genomics Medicine and Molecular Diagnostics: The Case of Sri Lanka
Current Pharmacogenomics and Personalized Medicine Lipoprotein(a) Management: Pharmacological and Apheretic Treatment
Current Medicinal Chemistry Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Therapeutic Targets to Raise HDL in Patients at Risk or with Coronary Artery Disease
Current Vascular Pharmacology The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Comparison Between the Effects of Bupivacaine and Levobupivacaine for Spinal Anesthesia on QT Dispersion
Cardiovascular & Hematological Disorders-Drug Targets Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors
Current HIV Research Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets